Adjuvant RCC After Nephrectomy: Risk, Surveillance, Pembrolizumab, and the Pembro/Belzutifan Decision

Authored by Natalia Gandur, published on 2026-07-09 08:58:25.0

Post-nephrectomy RCC: confirm pathology, stage, nodal status, sarcomatoid features, M1 NED status, and restaging

Begin with a structured postoperative assessment after nephrectomy. Confirm: - Histology and presence or absence of clear-cell component. - Pathologic T stage. - Tumor grade. - Nodal status. - Sarcomatoid features. - Rhabdoid features, if reported. - Margin status, if relevant. - Whether metastatic lesions were completely resected. - Postoperative imaging status. - ECOG performance status. - Recovery from surgery. - Renal function and relevant comorbidities. - Baseline hemoglobin and oxygen saturation if belzutifan-containing therapy may be considered. - Patient preferences and access constraints. This pathway applies only after confirming no active measurable disease.
- Active measurable disease or unresected metastases?
  
  This pathway is intended for patients without evidence of active measurable disease after nephrectomy, with or without complete resection of metastatic lesions. If active measurable disease, unresected metastases, or radiographic recurrence is present, route to an advanced/metastatic RCC pathway rather than an adjuvant pathway. Do not use this pathway to make fixed systemic therapy recommendations for active metastatic RCC.
  - YES
    - Advanced / metastatic RCC pathway
  - NO
    - Clear-cell component?
      
      The evidence base for adjuvant pembrolizumab and pembrolizumab plus belzutifan is centered on renal cell carcinoma with a clear-cell component. For non–clear-cell RCC without a clear-cell component, avoid extrapolating this pathway as a standard adjuvant systemic therapy recommendation. Consider surveillance, clinical trial enrollment, and individualized multidisciplinary discussion.
      - NO
        
        Surveillance / clinical trial / individualized discussion
      - YES
        
        Postoperative recurrence risk: lower vs intermediate-high / high vs M1 NED
        
        Risk assessment should integrate pathologic stage, grade, nodal status, sarcomatoid features when included in risk criteria, and whether the patient is M1 NED after complete resection of metastatic disease. Use KEYNOTE-564-style risk groups as the clinical anchor: Intermediate-high risk: - pT2, grade 4 or sarcomatoid features, N0 M0. - pT3, any grade, N0 M0. High risk: - pT4, any grade, N0 M0. - Any pT, any grade, N+ M0. M1 no evidence of disease: - No evidence of disease after complete resection of metastatic sites, generally within one year from nephrectomy in the KEYNOTE-564 framework. Lower-risk patients should generally be routed to surveillance because the expected absolute benefit of adjuvant systemic therapy may be limited and overtreatment is a concern. Sarcomatoid features may contribute to recurrence-risk classification when included in risk criteria, but they should not drive a separate treatment-selection branch for pembrolizumab + belzutifan.
        
        LOWER RISK
        
        SURVEILLANCE
        
        Surveillance is an active postoperative management strategy, not undertreatment. Best fit: - Lower recurrence risk. - Uncertain or low expected absolute benefit from adjuvant systemic therapy. - Non–clear-cell RCC without a clear-cell component. - Contraindication to immune checkpoint inhibitor therapy. - Major competing comorbidity, frailty, or limited treatment tolerance. - Patient preference to avoid adjuvant systemic therapy after shared decision-making. - Lack of access or reimbursement for adjuvant therapy. Practical surveillance components: - History and physical examination. - Review of symptoms suggestive of recurrence. - Blood pressure and general medical optimization. - CBC and chemistry panel as clinically appropriate. - Renal function monitoring after nephrectomy. - Cross-sectional imaging of chest/abdomen/pelvis according to recurrence risk and institutional or guideline-based follow-up schedules. - Consider MRI abdomen if iodinated contrast is not appropriate. - Educate patient about symptoms that should trigger earlier assessment. If recurrence is detected: - Confirm whether recurrence is local, oligometastatic, or systemic. - Consider local therapy for selected isolated/local or oligometastatic recurrence. - Route systemic recurrence to an advanced RCC pathway.
        
        INTERMEDIATE-HIGH / HIGH / M1 NED
        
        Candidate for adjuvant systemic therapy?
        
        Assess whether adjuvant systemic therapy is clinically appropriate before selecting a regimen. Key inputs: - Adequate recovery from nephrectomy. - No active measurable disease on postoperative assessment. - ECOG performance status. - Autoimmune disease history or need for immunosuppression. - Baseline renal, hepatic, endocrine, and pulmonary status. - Baseline hemoglobin. - Baseline oxygen saturation. - Baseline pregnancy status and contraception considerations when relevant. - Competing comorbidities and frailty. - Patient values and willingness to accept adjuvant toxicity for recurrence-risk reduction. - Access, reimbursement, and local regulatory status. If the patient is not fit for immune checkpoint inhibitor therapy, has major competing comorbidity, has low expected absolute benefit, or prefers to avoid systemic therapy after shared decision-making, surveillance remains appropriate.
        
        NO / NOT FIT
        
        SUEVEILLANCE
        
        Surveillance is an active postoperative management strategy, not undertreatment. Best fit: - Lower recurrence risk. - Uncertain or low expected absolute benefit from adjuvant systemic therapy. - Non–clear-cell RCC without a clear-cell component. - Contraindication to immune checkpoint inhibitor therapy. - Major competing comorbidity, frailty, or limited treatment tolerance. - Patient preference to avoid adjuvant systemic therapy after shared decision-making. - Lack of access or reimbursement for adjuvant therapy. Practical surveillance components: - History and physical examination. - Review of symptoms suggestive of recurrence. - Blood pressure and general medical optimization. - CBC and chemistry panel as clinically appropriate. - Renal function monitoring after nephrectomy. - Cross-sectional imaging of chest/abdomen/pelvis according to recurrence risk and institutional or guideline-based follow-up schedules. - Consider MRI abdomen if iodinated contrast is not appropriate. - Educate patient about symptoms that should trigger earlier assessment. If recurrence is detected: - Confirm whether recurrence is local, oligometastatic, or systemic. - Consider local therapy for selected isolated/local or oligometastatic recurrence. - Route systemic recurrence to an advanced RCC pathway.
        
        YES / FIT
        
        Select adjuvant strategy after shared decision-making
        
        Adjuvant strategy selection should integrate recurrence risk, clear-cell histology / clear-cell component, postoperative recovery, treatment fitness, expected benefit, toxicity profile, monitoring burden, access, and patient preference. Available strategies: - Surveillance. - Adjuvant pembrolizumab. - Adjuvant pembrolizumab + belzutifan where approved and available. Pembrolizumab remains the established adjuvant PD-1 anchor with DFS and OS benefit in KEYNOTE-564-eligible patients. Pembrolizumab + belzutifan should be positioned as a preferred adjuvant option where approved and available for eligible patients with RCC with a clear-cell component at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions. Pembrolizumab monotherapy remains appropriate when pembrolizumab + belzutifan is not approved, not available, contraindicated, not tolerated, or when added anemia/hypoxia monitoring and toxicity burden are not clinically appropriate. Avoid presenting pembrolizumab + belzutifan as applicable to non–clear-cell RCC without a clear-cell component.
        
        SURVEILLANCE
        
        Surveillance is an active postoperative management strategy, not undertreatment. Best fit: - Lower recurrence risk. - Uncertain or low expected absolute benefit from adjuvant systemic therapy. - Non–clear-cell RCC without a clear-cell component. - Contraindication to immune checkpoint inhibitor therapy. - Major competing comorbidity, frailty, or limited treatment tolerance. - Patient preference to avoid adjuvant systemic therapy after shared decision-making. - Lack of access or reimbursement for adjuvant therapy. Practical surveillance components: - History and physical examination. - Review of symptoms suggestive of recurrence. - Blood pressure and general medical optimization. - CBC and chemistry panel as clinically appropriate. - Renal function monitoring after nephrectomy. - Cross-sectional imaging of chest/abdomen/pelvis according to recurrence risk and institutional or guideline-based follow-up schedules. - Consider MRI abdomen if iodinated contrast is not appropriate. - Educate patient about symptoms that should trigger earlier assessment. If recurrence is detected: - Confirm whether recurrence is local, oligometastatic, or systemic. - Consider local therapy for selected isolated/local or oligometastatic recurrence. - Route systemic recurrence to an advanced RCC pathway.
        
        Surveillance: risk-adapted imaging and clinical follow-up
        
        Recurrence during or after adjuvant therapy
        
        This pathway should not provide a fixed systemic sequencing algorithm after recurrence. If recurrence is detected: - Confirm recurrence with appropriate imaging. - Define recurrence pattern: local, oligometastatic, or systemic. - Consider biopsy if diagnosis is uncertain or if histology may affect management. - Confirm timing relative to adjuvant therapy: - During adjuvant therapy. - Within 6 months after completing adjuvant therapy. - 6–12 months after completing adjuvant therapy. - More than 12 months after completing adjuvant therapy. - Document prior adjuvant exposure: - Surveillance only. - Pembrolizumab. - Pembrolizumab + belzutifan. - Document prior immune-related toxicity or belzutifan-related anemia/hypoxia. - Assess disease burden, symptoms, pace of recurrence, sites of disease, performance status, renal function, and comorbidities. Management direction: - Local recurrence or oligometastatic recurrence: consider multidisciplinary review for local therapy when appropriate. - Systemic recurrence: route to advanced/metastatic RCC pathway. - Recurrence during or shortly after adjuvant PD-1-based therapy: avoid automatic PD-1 rechallenge logic. - Recurrence after pembrolizumab + belzutifan: route to advanced RCC sequencing pathway and consider prior exposure to both PD-1 and HIF-2α inhibition. Implementation note: This node is a routing node, not a treatment-selection node. It should direct clinicians to a dedicated advanced RCC sequencing pathway rather than embedding a complex post-adjuvant treatment algorithm here.
        
        PEMBROLIZUMAB
        
        Adjuvant pembrolizumab is the established PD-1 anchor for selected patients with RCC with a clear-cell component at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and complete resection of metastatic lesions. Best fit: - RCC with clear-cell component. - Intermediate-high or high recurrence risk. - M1 NED after complete resection of metastatic disease. - Adequate recovery from surgery. - Fit for immune checkpoint inhibitor therapy. - No uncontrolled autoimmune disease requiring significant immunosuppression. - Patient accepts immune-related toxicity risk after shared decision-making. Clinical positioning: Pembrolizumab remains appropriate when pembrolizumab + belzutifan is not approved, not available, contraindicated, not tolerated, or when added anemia/hypoxia monitoring and toxicity burden are not clinically appropriate. Dose / schedule: - Pembrolizumab 200 mg IV every 3 weeks, or - Pembrolizumab 400 mg IV every 6 weeks. - Continue until disease recurrence, unacceptable toxicity, or up to 12 months. Baseline assessment: - Confirm no active measurable disease on postoperative imaging. - ECOG performance status. - CBC. - Comprehensive metabolic panel, including creatinine/eGFR, AST/ALT, bilirubin, and electrolytes. - Thyroid function: TSH ± free T4. - Baseline glucose; HbA1c if diabetic or clinically indicated. - Pregnancy test if applicable. - Review autoimmune disease, transplant history, baseline steroids/immunosuppression, interstitial lung disease, and prior immune toxicity. - Review medication list and comorbidities. Monitoring during therapy: - Clinical review before each cycle. - CBC and chemistry panel before each cycle or per institutional practice. - TSH/free T4 periodically. - Monitor for diarrhea/colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, skin toxicity, neurologic symptoms, infusion reactions, and fatigue. - Educate patients to report diarrhea, cough, dyspnea, rash, jaundice, severe fatigue, headache, visual symptoms, polyuria/polydipsia, or new neurologic symptoms. Implementation note: Immune-related adverse events can occur during treatment or after discontinuation. Manage significant immune-related toxicity according to institutional immune-toxicity guidelines or a dedicated irAE pathway.
        
        Adjuvant pembrolizumab: established PD-1 anchor; DFS and OS benefit in KEYNOTE-564-eligible patients
        
        MONITOR AND SAFETY
        
        Pembrolizumab safety monitoring should focus on immune-mediated adverse events, infusion reactions, and delayed toxicities. Baseline: - CBC. - Comprehensive metabolic panel. - Creatinine/eGFR. - AST/ALT and bilirubin. - TSH ± free T4. - Baseline glucose; HbA1c if clinically indicated. - Pregnancy test if applicable. - Review autoimmune disease, transplant history, baseline steroids, and immunosuppression. - Review pulmonary symptoms or history of interstitial lung disease. During treatment: - Clinical review before each cycle. - CBC and chemistry panel before each cycle or per institutional practice. - TSH/free T4 periodically. - Evaluate for diarrhea, abdominal pain, blood in stool, cough, dyspnea, rash, pruritus, severe fatigue, headache, visual symptoms, jaundice, dark urine, polyuria/polydipsia, or neurologic symptoms. Toxicity domains: - Colitis. - Hepatitis. - Pneumonitis. - Endocrinopathies, including thyroiditis, hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, and diabetes. - Nephritis. - Skin toxicity. - Neurologic immune-mediated events. - Infusion reactions. Implementation note: Immune-related adverse events can occur during treatment or after discontinuation. The pathway should not provide detailed steroid algorithms unless linked to a dedicated immune-toxicity management module.
        
        Pembrolizumab safety: immune-related toxicity monitoring
        
        Recurrence during or after adjuvant therapy
        
        This pathway should not provide a fixed systemic sequencing algorithm after recurrence. If recurrence is detected: - Confirm recurrence with appropriate imaging. - Define recurrence pattern: local, oligometastatic, or systemic. - Consider biopsy if diagnosis is uncertain or if histology may affect management. - Confirm timing relative to adjuvant therapy: - During adjuvant therapy. - Within 6 months after completing adjuvant therapy. - 6–12 months after completing adjuvant therapy. - More than 12 months after completing adjuvant therapy. - Document prior adjuvant exposure: - Surveillance only. - Pembrolizumab. - Pembrolizumab + belzutifan. - Document prior immune-related toxicity or belzutifan-related anemia/hypoxia. - Assess disease burden, symptoms, pace of recurrence, sites of disease, performance status, renal function, and comorbidities. Management direction: - Local recurrence or oligometastatic recurrence: consider multidisciplinary review for local therapy when appropriate. - Systemic recurrence: route to advanced/metastatic RCC pathway. - Recurrence during or shortly after adjuvant PD-1-based therapy: avoid automatic PD-1 rechallenge logic. - Recurrence after pembrolizumab + belzutifan: route to advanced RCC sequencing pathway and consider prior exposure to both PD-1 and HIF-2α inhibition. Implementation note: This node is a routing node, not a treatment-selection node. It should direct clinicians to a dedicated advanced RCC sequencing pathway rather than embedding a complex post-adjuvant treatment algorithm here.
        
        PEMBRO + BELZUTIFAN
        
        Pembrolizumab + belzutifan is an intensified adjuvant option where approved and available for adults with RCC with a clear-cell component at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and complete resection of metastatic lesions. This strategy should emphasize: - Clear-cell histology / clear-cell component. - Intermediate-high or high recurrence risk. - M1 NED after complete resection, when otherwise appropriate. - Adequate postoperative recovery. - Fitness for both immune checkpoint inhibitor therapy and belzutifan. - Acceptable baseline hemoglobin. - Acceptable baseline oxygen saturation and pulmonary status. - No major uncontrolled pulmonary disease or symptomatic hypoxia. - Ability to comply with anemia and hypoxia monitoring. - Access in a jurisdiction where the regimen is approved and available. Clinical positioning: - This should not be restricted only to narrowly selected subgroups. - Pembrolizumab + belzutifan may be favored where approved and available for eligible patients with a clear-cell component who are fit for combination therapy. - Pembrolizumab monotherapy remains appropriate when belzutifan is not approved, not available, contraindicated, not tolerated, or when added anemia/hypoxia monitoring and toxicity burden are not clinically appropriate. Evidence note: LITESPARK-022 demonstrated improved disease-free survival with pembrolizumab + belzutifan compared with pembrolizumab + placebo. Overall survival data were not mature at the prespecified interim analysis. Do not use this branch for: - Non–clear-cell RCC without a clear-cell component. - Active measurable metastatic disease. - Patients with recurrence already present on postoperative imaging. - Patients not fit for the combination after clinical assessment. Best fit: - RCC with clear-cell component. - Intermediate-high or high recurrence risk. - M1 NED after complete metastasectomy, if otherwise appropriate. - Fit for both PD-1 therapy and belzutifan. - Adequate postoperative recovery. - Acceptable baseline hemoglobin. - Acceptable baseline oxygen saturation and pulmonary status. - No major uncontrolled pulmonary disease or symptomatic hypoxia. - Patient accepts higher toxicity and monitoring burden. - Access in a jurisdiction where the regimen is approved and available. Dose / schedule: - Belzutifan 120 mg orally once daily, with or without food. - Pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks. - Continue until disease recurrence, unacceptable toxicity, or up to 54 weeks of belzutifan and up to 12 months of pembrolizumab. Baseline assessment: - Confirm no active measurable disease on postoperative imaging. - ECOG performance status. - CBC with hemoglobin. - Comprehensive metabolic panel, including creatinine/eGFR, AST/ALT, bilirubin, electrolytes. - Thyroid function: TSH ± free T4. - Baseline oxygen saturation at rest. - Consider exertional oxygen saturation if pulmonary disease, dyspnea, high altitude, or borderline resting saturation. - Baseline iron studies to identify iron deficiency: ferritin, iron, transferrin saturation/TIBC, according to local practice. - Pregnancy test if applicable. - Review contraception and embryo-fetal toxicity risk. - Review autoimmune disease and immune checkpoint inhibitor fitness. - Review pulmonary disease, sleep apnea, cardiopulmonary comorbidity, and baseline anemia. - Medication review, including CYP3A4 considerations and hormonal contraceptive efficacy. Monitoring during therapy: - Clinical assessment before each pembrolizumab cycle. - CBC and chemistry panel before each cycle or per institutional practice. - Hemoglobin monitoring before initiation and periodically throughout treatment. - Oxygen saturation before initiation and periodically throughout treatment. - Monitor for immune-related toxicities from pembrolizumab. - Monitor for anemia, hypoxia, fatigue, dyspnea, dizziness, and reduced exercise tolerance from belzutifan. - Counsel patient to report shortness of breath, worsening fatigue, dizziness, palpitations, chest symptoms, or new/worsening hypoxia symptoms. Belzutifan dose modification anchor: - Starting dose: 120 mg orally once daily. - First dose reduction: 80 mg orally once daily. - Second dose reduction: 40 mg orally once daily. - Third dose reduction: permanently discontinue. Anemia management: - If hemoglobin <9 g/dL or transfusion is indicated, withhold belzutifan until hemoglobin is ≥9 g/dL. - Resume at the same or reduced dose, or discontinue depending on severity. - For life-threatening anemia or urgent intervention, withhold until hemoglobin is ≥9 g/dL, then resume at reduced dose once resolved or permanently discontinue. - Transfuse as clinically indicated. - Baseline iron studies are sufficient to assess for iron deficiency; IV iron can be used to optimize iron status in iron-deficient patients in expert practice. - Intensive iron-study follow-up is not required beyond yearly reassessment unless clinically indicated. Hypoxia management: - For decreased oxygen saturation with exercise, consider withholding belzutifan until resolved, then resume at same or reduced dose depending on severity. - For decreased oxygen saturation at rest or urgent intervention, withhold until resolved and resume at reduced dose or discontinue depending on severity. - For life-threatening hypoxia or recurrent symptomatic hypoxia, permanently discontinue belzutifan. Clinical positioning: Frame this as an intensified adjuvant option, not as a universal default. Suggested language: “Consider pembrolizumab + belzutifan where approved, available, and clinically appropriate after shared decision-making, particularly in patients with sufficiently high recurrence risk who are fit for added belzutifan-related monitoring and toxicity.”
        
        Pembrolizumab + belzutifan: where approved/available; DFS benefit vs pembrolizumab alone; OS not significant at interim analysis; higher grade ≥3 toxicity
        
        MONITOR AND SAFETY
        
        This node applies to patients receiving adjuvant pembrolizumab + belzutifan where approved and available. Dose / schedule: - Belzutifan 120 mg orally once daily, with or without food. - Pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks. - Continue until disease recurrence, unacceptable toxicity, or up to 54 weeks of belzutifan and up to 12 months of pembrolizumab. Baseline clinical assessment: - Confirm no active measurable disease on postoperative imaging. - Confirm adequate recovery from nephrectomy. - ECOG performance status. - Review autoimmune disease, transplant history, baseline steroids, or immunosuppression. - Review pulmonary disease, sleep apnea, cardiopulmonary comorbidity, baseline anemia, and baseline dyspnea. - Review pregnancy potential, contraception, fertility considerations, and lactation. - Review medication list for drug interactions, including CYP3A4 substrate considerations and hormonal contraceptive efficacy. Baseline laboratory / safety workup: - CBC with hemoglobin. - Comprehensive metabolic panel. - Creatinine/eGFR. - AST/ALT, bilirubin, alkaline phosphatase. - Electrolytes. - TSH ± free T4. - Baseline glucose; HbA1c if diabetic or clinically indicated. - Baseline oxygen saturation at rest. - Consider exertional oxygen saturation in patients with dyspnea, pulmonary disease, borderline resting saturation, sleep apnea, high-altitude exposure, or reduced exercise tolerance. - Baseline iron studies to assess iron deficiency: ferritin, serum iron, transferrin saturation/TIBC according to local practice. - Pregnancy test if applicable. Monitoring during therapy: - Clinical assessment before each pembrolizumab cycle. - CBC and chemistry panel before each cycle or per institutional practice. - Hemoglobin before initiation and periodically throughout belzutifan treatment. - Oxygen saturation before initiation and periodically throughout belzutifan treatment. - Thyroid function periodically. - Symptom review for fatigue, dyspnea, dizziness, reduced exercise tolerance, palpitations, chest symptoms, diarrhea, rash, cough, jaundice, abdominal pain, headache, visual symptoms, polyuria/polydipsia, and neurologic symptoms. Pembrolizumab toxicity monitoring: - Monitor for immune-mediated adverse reactions. - Key domains: colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, dermatologic toxicity, neurologic toxicity, and infusion reactions. - Immune-related adverse events can occur during treatment or after discontinuation. - Manage significant immune-related toxicity according to institutional immune-toxicity guidelines or a dedicated irAE pathway. Belzutifan dose modification anchor: - Starting dose: 120 mg orally once daily. - First dose reduction: 80 mg orally once daily. - Second dose reduction: 40 mg orally once daily. - Third dose reduction: permanently discontinue. Anemia management: - Withhold belzutifan if hemoglobin <9 g/dL or transfusion is indicated until hemoglobin is ≥9 g/dL. - Resume belzutifan at the same or reduced dose, or discontinue depending on severity. - For life-threatening anemia or urgent intervention, withhold belzutifan until hemoglobin is ≥9 g/dL, then resume at reduced dose once resolved or permanently discontinue. - Transfuse as clinically indicated. - Baseline iron studies are sufficient to assess for iron deficiency. - IV iron can be used to optimize iron status in iron-deficient patients in expert practice. - Intensive serial iron-study follow-up is not required beyond yearly reassessment unless clinically indicated. Hypoxia management: - For decreased oxygen saturation with exercise, consider withholding belzutifan until resolved, then resume at the same or reduced dose depending on severity. - For decreased oxygen saturation at rest or urgent intervention, withhold belzutifan until resolved, then resume at reduced dose or discontinue depending on severity. - Permanently discontinue belzutifan for life-threatening hypoxia or recurrent symptomatic hypoxia. - Advise patients to report shortness of breath, worsening fatigue, dizziness, palpitations, chest symptoms, or new/worsening hypoxia symptoms immediately. Reproductive safety: - Verify pregnancy status before starting belzutifan when applicable. - Counsel that belzutifan can cause embryo-fetal harm. - Use effective non-hormonal contraception during treatment and for 1 week after the last belzutifan dose when relevant. - Belzutifan may reduce the effectiveness of some hormonal contraceptives. - Advise against breastfeeding during treatment and for 1 week after the last dose. Implementation note:This combination requires both immune-toxicity readiness and belzutifan-specific anemia/hypoxia monitoring. Link the live Belzutifan Practical Guidance pathway as a companion safety reference.
        
        pembrolizumab + belzutifan
        
        This node applies to patients receiving adjuvant pembrolizumab + belzutifan where approved and available. Dose / schedule: - Belzutifan 120 mg orally once daily, with or without food. - Pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks. - Continue until disease recurrence, unacceptable toxicity, or up to 54 weeks of belzutifan and up to 12 months of pembrolizumab. Baseline clinical assessment: - Confirm no active measurable disease on postoperative imaging. - Confirm adequate recovery from nephrectomy. - ECOG performance status. - Review autoimmune disease, transplant history, baseline steroids or immunosuppression. - Review pulmonary disease, sleep apnea, cardiopulmonary comorbidity, baseline anemia, and baseline dyspnea. - Review pregnancy potential, contraception, fertility considerations, and lactation. - Review medication list for drug interactions, including CYP3A4 substrate considerations and hormonal contraceptive efficacy. Baseline laboratory / safety workup: - CBC with hemoglobin. - Comprehensive metabolic panel. - Creatinine/eGFR. - AST/ALT, bilirubin, alkaline phosphatase. - Electrolytes. - TSH ± free T4. - Baseline glucose; HbA1c if diabetic or clinically indicated. - Baseline oxygen saturation at rest. - Consider exertional oxygen saturation in patients with dyspnea, pulmonary disease, borderline resting saturation, sleep apnea, high altitude exposure, or reduced exercise tolerance. - Baseline iron studies to assess iron deficiency: ferritin, serum iron, transferrin saturation/TIBC according to local practice. - Pregnancy test if applicable. Monitoring during therapy: - Clinical assessment before each pembrolizumab cycle. - CBC and chemistry panel before each cycle or per institutional practice. - Hemoglobin before initiation and periodically throughout belzutifan treatment. - Oxygen saturation before initiation and periodically throughout belzutifan treatment. - Thyroid function periodically. - Symptom review for fatigue, dyspnea, dizziness, reduced exercise tolerance, palpitations, chest symptoms, diarrhea, rash, cough, jaundice, abdominal pain, headache, visual symptoms, polyuria/polydipsia, and neurologic symptoms. Pembrolizumab toxicity monitoring: - Monitor for immune-mediated adverse reactions. - Key domains: colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, dermatologic toxicity, neurologic toxicity, and infusion reactions. - Immune-related adverse events can occur during treatment or after discontinuation. - Manage significant immune-related toxicity according to institutional immune-toxicity guidelines or dedicated irAE pathway. Belzutifan dose modification anchor: - Starting dose: 120 mg orally once daily. - First dose reduction: 80 mg orally once daily. - Second dose reduction: 40 mg orally once daily. - Third dose reduction: permanently discontinue. Anemia management: - Withhold belzutifan if hemoglobin <9 g/dL or transfusion is indicated until hemoglobin is ≥9 g/dL. - Resume belzutifan at the same or reduced dose, or discontinue depending on severity. - For life-threatening anemia or urgent intervention, withhold belzutifan until hemoglobin is ≥9 g/dL, then resume at reduced dose once resolved or permanently discontinue. - Transfuse as clinically indicated. - Baseline iron studies are sufficient to assess for iron deficiency. - IV iron can be used to optimize iron status in iron-deficient patients in expert practice. - Intensive serial iron-study follow-up is not required beyond yearly reassessment unless clinically indicated. Hypoxia management: - For decreased oxygen saturation with exercise, consider withholding belzutifan until resolved, then resume at the same or reduced dose depending on severity. - For decreased oxygen saturation at rest or urgent intervention, withhold belzutifan until resolved, then resume at reduced dose or discontinue depending on severity. - Permanently discontinue belzutifan for life-threatening hypoxia or recurrent symptomatic hypoxia. - Advise patients to report shortness of breath, worsening fatigue, dizziness, palpitations, chest symptoms, or new/worsening hypoxia symptoms immediately. Reproductive safety: - Verify pregnancy status before starting belzutifan when applicable. - Counsel that belzutifan can cause embryo-fetal harm. - Use effective non-hormonal contraception during treatment and for 1 week after the last belzutifan dose when relevant. - Belzutifan may reduce effectiveness of some hormonal contraceptives. - Advise against breastfeeding during treatment and for 1 week after the last dose. Implementation note:This combination requires both immune-toxicity readiness and belzutifan-specific anemia/hypoxia monitoring. Link the live Belzutifan Practical Guidance pathway as a companion safety reference.
        
        Recurrence during or after adjuvant therapy
        
        This pathway should not provide a fixed systemic sequencing algorithm after recurrence. If recurrence is detected: - Confirm recurrence with appropriate imaging. - Define recurrence pattern: local, oligometastatic, or systemic. - Consider biopsy if diagnosis is uncertain or if histology may affect management. - Confirm timing relative to adjuvant therapy: - During adjuvant therapy. - Within 6 months after completing adjuvant therapy. - 6–12 months after completing adjuvant therapy. - More than 12 months after completing adjuvant therapy. - Document prior adjuvant exposure: - Surveillance only. - Pembrolizumab. - Pembrolizumab + belzutifan. - Document prior immune-related toxicity or belzutifan-related anemia/hypoxia. - Assess disease burden, symptoms, pace of recurrence, sites of disease, performance status, renal function, and comorbidities. Management direction: - Local recurrence or oligometastatic recurrence: consider multidisciplinary review for local therapy when appropriate. - Systemic recurrence: route to advanced/metastatic RCC pathway. - Recurrence during or shortly after adjuvant PD-1-based therapy: avoid automatic PD-1 rechallenge logic. - Recurrence after pembrolizumab + belzutifan: route to advanced RCC sequencing pathway and consider prior exposure to both PD-1 and HIF-2α inhibition. Implementation note: This node is a routing node, not a treatment-selection node. It should direct clinicians to a dedicated advanced RCC sequencing pathway rather than embedding a complex post-adjuvant treatment algorithm here.
        
        Faculty nuance / expert discussion
        
        Key clinical nuances: 1. Clear-cell component: Pembrolizumab + belzutifan should be used only in RCC with a clear-cell component within the approved and evidence-supported population. 2. Positioning of pembrolizumab + belzutifan: Where approved and available, pembrolizumab + belzutifan should be positioned as a preferred adjuvant option for eligible patients, not only for narrowly selected subgroups. 3. Pembrolizumab monotherapy: Pembrolizumab remains appropriate when belzutifan is not approved, not available, contraindicated, not tolerated, or when added anemia/hypoxia monitoring and toxicity burden are not clinically appropriate. 4. Sarcomatoid features: Sarcomatoid features may contribute to recurrence-risk classification when included in risk criteria, but they should not drive a separate treatment-selection branch. 5. OS maturity: LITESPARK-022 demonstrated disease-free survival benefit with pembrolizumab + belzutifan. Overall survival data were not mature at the prespecified interim analysis. 6. Monitoring burden: Pembrolizumab + belzutifan requires both immune-toxicity monitoring and belzutifan-specific monitoring for anemia, hypoxia, reproductive safety, and drug interactions. 7. Global applicability: Use “where approved and available” to avoid overgeneralizing across jurisdictions. 8. Recurrence routing: Recurrence during or after adjuvant therapy should be routed to a dedicated advanced RCC pathway. This adjuvant pathway should not embed a fixed post-adjuvant systemic sequencing algorithm.

tos privacy Choueiri TK, Motzer RJ, Karam JA, et al. Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma. N Engl J Med. 2026;395:32-43.European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: disease management. 2026.FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683-694.Powles T, Albiges L, Bex A, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:692-706.European Association of Urology. EAU Guidelines on Renal Cell Carcinoma: adjuvant pembrolizumab risk groups. 2026.FDA-approved prescribing information for pembrolizumab includes immune-mediated adverse reactions and infusion-related reactions.ESMO RCC Clinical Practice Guideline covers treatment and follow-up algorithms for localized and advanced RCC.Choueiri TK, Tomczak P, Park SH, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024;390:1359-1371.U.S. Food and Drug Administration. FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. 2026.DailyMed. WELIREG belzutifan prescribing information. 2026 update.Pembrolizumab Is First Adjuvant Therapy to Improve Overall Survival in Kidney Cancer Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435.Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073-4126.DailyMed. WELIREG belzutifan tablet prescribing information: dosage modifications, anemia, hypoxia.